VistaGen Therapeutics, Inc.
General ticker "VTGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $88.1M (TTM average)
VistaGen Therapeutics, Inc. follows the US Stock Market performance with the rate: 49.3%.
Estimated limits based on current volatility of 9.1%: low 3.59$, high 4.31$
Factors to consider:
- Total employees count: 39 (+18.2%) as of 2024
- Top business risk factors: Clinical trial failures, Regulatory and compliance, Preclinical issues, Proprietary rights, Post approval issues
- Current price 15.6% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [1.25$, 3.70$]
- 2026-03-31 to 2027-03-31 estimated range: [0.80$, 2.48$]
Financial Metrics affecting the VTGN estimates:
- Positive: with PPE of -1.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -50.69 <= 0.33
- Positive: Shareholder equity ratio, % of 83.46 > 63.39
- Negative: Industry earnings per price (median), % of -16.46 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VTGN quotes
Long-term VTGN plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $1.06MM | $0.49MM |
| Operating Expenses | $59.27MM | $34.09MM | $56.46MM |
| Operating Income | $-59.27MM | $-33.02MM | $-55.97MM |
| Non-Operating Income | $0.03MM | $3.66MM | $4.56MM |
| R&D Expense | $44.38MM | $20.02MM | $39.38MM |
| Income(Loss) | $-59.24MM | $-29.36MM | $-51.41MM |
| Taxes | $0.01MM | $0.00MM | $0.01MM |
| Profit(Loss)* | $-59.25MM | $-29.36MM | $-51.42MM |
| Stockholders Equity | $12.08MM | $114.29MM | $70.39MM |
| Assets | $21.09MM | $123.65MM | $84.34MM |
| Operating Cash Flow | $-49.72MM | $-25.81MM | $-42.10MM |
| Capital expenditure | $0.21MM | $0.06MM | $0.19MM |
| Investing Cash Flow | $-0.74MM | $-0.06MM | $-13.15MM |
| Financing Cash Flow | $-1.04MM | $128.40MM | $3.21MM |
| Earnings Per Share** | $-8.51 | $-1.52 | $-1.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.